Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.42 |
| ▸ | CDC25B | P30305 | 6/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GJB2 | P29033 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17114324 | 1.00 | HTR1A (0.50) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL17114325 | 1.00 | HTR1A (0.50) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL260046 | 1.00 | HTR1A (0.50) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL260045 | 1.00 | HTR1A (0.50) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL264459 | 0.95 | SSTR1 (0.50) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL259552 | 0.95 | SSTR1 (0.50) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL14064149 | 0.95 | SSTR1 (0.50) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL27424638 | 0.89 | PDE2A (0.46) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL10409398 | 0.86 | HTR1A (0.48) | HTR1ABCHEACHENT5ESSTR1 | |
| SCHEMBL10408093 | 0.86 | HTR1A (0.48) | HTR1ABCHEACHENT5ESSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994604-B2 | Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them | BIO-LAB LTD. (IL) | 2018-06-12 | — | — | US | disclosed |
| US-20150141490-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | BIO-LAB LTD. (IL) | 2015-05-21 | — | — | US | disclosed |
| US-20130078218-A1 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | disclosed |
| EP-2537520-A1 | Hepatics C therapies | Biocryst Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1863500-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060234963-A1 | Hepatitis C therapies | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-10-19 | — | — | US | disclosed |
| WO-2006104945-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | HTR1A 4285/4885BCHE 4567/4885ACHE 4773/4885 |
| US-20130078218-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | HTR1A 4620/4885BCHE 1956/4885ACHE 4632/4885 |
| US-20060234963-A1 | Hepatitis C therapies | HAVCR2, FABP1, LIPC | HTR1A 4620/4885BCHE 1956/4885ACHE 4632/4885 |
| US-20150141490-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | NT5C2, TK2, DUT | HTR1A 3708/4885BCHE 4671/4885ACHE 4609/4885 |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | DPYD, TYMP, TYMS | HTR1A 4285/4885BCHE 4567/4885ACHE 4773/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | HTR1A 4285/4885BCHE 4567/4885ACHE 4773/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | HTR1A 4620/4885BCHE 1956/4885ACHE 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.